Table 2

Pluripotent stem cell clinical trials (USA)

Trial sponsor

Disease target

Cell therapy


Geron Inc.

Phase I: 10 patients

enrolled 2010-12

Complete subacute thoracic spinal cord injuries. T3 to T10 segments between seven and 14 days after injury

Human embryonic stem cell derived Oligodendrocyte progenitor cells (GRNOPC1)

Advanced Cell Technologies (ACT)

Phase I/II: 12 patients Enrolled 2011

Stargardt's Macular Dystrophy (juvenile macular degeneration)

Retinal Pigment Epithelium derived from human embryonic stem cells

Advanced Cell Technologies (ACT)

Phase I/II: 12 patients Enrolled 2011-12

Age-related Macular Degeneration

Retinal Pigment Epithelium derived from human embryonic stem cells

California Stem Cell (CSC)

Phase I

Currently on hold 2011

Spinal muscular atrophy (SMA) Type 1

Human motor neuron progenitor cells derived from human embryonic stem cells


Trounson et al. BMC Medicine 2011 9:52   doi:10.1186/1741-7015-9-52

Open Data